Auto Amazon Links: No products found.
A recent clinical trial has demonstrated that a new personalized cancer vaccine, when combined with a widely used immunotherapy drug, can significantly reduce the likelihood of death or recurrence in skin cancer patients. Specifically, the study showed a 42% decrease in the risk of either dying or having melanoma return. This breakthrough has been hailed by researchers as a potential milestone in advancing personalized medicine within cancer treatment.
The trial targeted patients who had undergone surgery to remove their tumors. Involving 1,137 participants, the study administered Keytruda—an immunotherapy medication that mobilizes the immune system to target cancer cells—to all patients. Approximately two-thirds of the group additionally received an experimental vaccine named Intismeran, which uses mRNA technology similar to some Covid-19 vaccines. This vaccine is customized for each patient based on genetic information from their tumor to help the immune system recognize and attack any returning cancer. Results after two years indicated that those vaccinated were substantially less likely to experience melanoma recurrence or metastasis.
Among the patients involved was Tony Chapman, aged 75, from Corby in the East Midlands. Diagnosed with melanoma in 2019, Tony initially had a tumor removed from his chest but developed a lump under his arm later, indicating the cancer had returned. After a second operation, he enrolled in the trial. Like other participants, Tony does not know if he received the vaccine or a placebo alongside his immunotherapy. Reflecting on his decision to join the study, Tony commented, “This just seemed like a really good example of moving science forward, as well as getting some benefit for yourself, so what’s to lose?” He remains cancer-free three years on, undergoing check-ups every six months.
While the companies behind the vaccine—MSD (known as Merck in the US) and Moderna—have seen their shares rise following the trial results, the stock market experienced a decline after analysts noted that these findings were not as strong as those from an earlier, smaller study. Both firms indicated plans to engage with regulatory authorities and potentially seek approval next year. However, widespread adoption within systems like the NHS will hinge on cost considerations, since each vaccine must be tailored to an individual’s tumor profile. Independent experts have praised the findings as promising but urge caution pending longer-term data to determine overall survival benefits. The full trial results are scheduled for presentation at an upcoming cancer conference in Madrid and have yet to appear in a peer-reviewed medical journal
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.